ABCL-351: Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL).

Details

Language :

English

ISSN :

21522650

Volume :

21

Database :

Complementary Index

Journal :

Clinical Lymphoma, Myeloma & Leukemia

Publication Type :

Academic Journal

Accession number :

152099213

Full Text :

https://doi.org/10.1016/S2152-2650(21)01892-9